414 related articles for article (PubMed ID: 9317196)
21. Dominant influence of gamma-globin promoter polymorphisms on fetal haemoglobin expression in sickle cell disease.
Ofori-Acquah SF; Lalloz MR; Serjeant G; Layton DM
Cell Mol Biol (Noisy-le-grand); 2004 Feb; 50(1):35-42. PubMed ID: 15040425
[TBL] [Abstract][Full Text] [Related]
22. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
[TBL] [Abstract][Full Text] [Related]
23. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
24. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1990 Apr; 322(15):1037-45. PubMed ID: 1690857
[TBL] [Abstract][Full Text] [Related]
25. Effect of hydroxyurea on immature reticulocyte fraction in sickle cell anemia.
Bagdasaryan R; Glasser L; Quillen K; Chaves F; Xu D
Lab Hematol; 2007; 13(3):93-7. PubMed ID: 17984040
[TBL] [Abstract][Full Text] [Related]
26. Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.
Bernaudin F; Arnaud C; Kamdem A; Hau I; Lelong F; Epaud R; Pondarré C; Pissard S
Blood Adv; 2018 Mar; 2(6):626-637. PubMed ID: 29555644
[TBL] [Abstract][Full Text] [Related]
27. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
28. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
29. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
[TBL] [Abstract][Full Text] [Related]
30. Fetal hemoglobin in sickle cell anemia: Bayesian modeling of genetic associations.
Sebastiani P; Wang L; Nolan VG; Melista E; Ma Q; Baldwin CT; Steinberg MH
Am J Hematol; 2008 Mar; 83(3):189-95. PubMed ID: 17918249
[TBL] [Abstract][Full Text] [Related]
31. Increasing fetal hemoglobin production in sickle cell disease: results of clinical trials.
Dover GJ; Charache S
Prog Clin Biol Res; 1987; 251():455-66. PubMed ID: 2448813
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic manipulation of fetal hemoglobin synthesis.
Dover GJ; Humphries RK; Young N; Ley T; Boyer S; Charache S; Nienhuis A
Prog Clin Biol Res; 1985; 191():447-54. PubMed ID: 2413480
[TBL] [Abstract][Full Text] [Related]
33. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
[TBL] [Abstract][Full Text] [Related]
34. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease.
Triadou P; Maier-Redelsperger M; Krishnamoorty R; Deschamps A; Casadevall N; Dunda O; Ducrocq R; Elion J; Girot R; Labie D
Nouv Rev Fr Hematol (1978); 1994 Oct; 36(5):367-72. PubMed ID: 7534399
[TBL] [Abstract][Full Text] [Related]
35. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
[TBL] [Abstract][Full Text] [Related]
37. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.
Tavakkoli F; Nahavandi M; Wyche MQ; Castro O
Clin Ther; 2005 Jul; 27(7):1083-8. PubMed ID: 16154487
[TBL] [Abstract][Full Text] [Related]
38. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
39. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
40. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
